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Abstract  36 
 37 
Objective: Higher systemic levels of proinflammatory biomarkers and low adiponectin are 38 
associated with increased risk for type 2 diabetes, but their associations with changes in 39 
glycaemic deterioration before onset of diabetes are poorly understood. We aimed to study 40 
whether inflammation-related biomarkers associated with 5-year changes in glucose and 41 
insulin, HbA1c, insulin sensitivity and beta-cell function before the diagnosis of type 2 42 
diabetes and whether these associations may be bidirectional.  43 
Design and Methods: We used multiple repeat measures (17,891 person-examinations from 44 
7,683 non-diabetic participants) from the Whitehall II study to assess whether circulating 45 
high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), IL-1 receptor antagonist 46 
(IL-1Ra) and adiponectin associated with subsequent changes in glycaemia, insulin, insulin 47 
resistance and beta-cell function (based on oral glucose tolerance tests). We examined 48 
bidirectionality by testing if parameters of glucose metabolism at baseline associated with 49 
changes in inflammation-related biomarkers.  50 
Results: Higher hsCRP and IL-6 were associated with increases in fasting insulin, insulin 51 
resistance and, for IL-6, with beta-cell function after adjustment for confounders. Higher 52 
adiponectin associated with decreases in fasting glucose, HbA1c, fasting insulin, insulin 53 
resistance and beta-cell function. The reverse approach showed that 2-hour glucose and 54 
insulin sensitivity associated in opposite directions with changes in IL-1Ra. Fasting insulin 55 
and insulin resistance showed inverse associations with changes in adiponectin.  56 
Conclusions: Subclinical inflammation associated with development of increased glycaemia, 57 
insulin resistance and beta-cell function in non-diabetic individuals. These findings are 58 
consistent with the hypothesis that inflammation-related processes may increase insulin 59 
resistance and lead to a compensatory upregulation of beta-cell function.  60 
  61 
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Introduction 62 
 63 
Biomarkers of subclinical inflammation are associated with incident type 2 diabetes (1,2), but 64 
prospective data on glycaemic deterioration before the onset of diabetes are scarce. Cross-65 
sectional studies suggest differential time-courses for changes in biomarkers of subclinical 66 
inflammation before type 2 diabetes. Regarding circulating C-reactive protein (CRP), for 67 
example, higher levels were observed in prediabetes (i.e. impaired fasting glucose (IFG) 68 
and/or impaired glucose tolerance (IGT)) compared to normal glucose tolerance (NGT), 69 
whereas only minor differences in CRP levels were observed between people with prediabetes 70 
and type 2 diabetes (3). In contrast, systemic levels of interleukin (IL)-6 or IL-18 seemed to 71 
be similar in individuals with NGT and prediabetes, but higher in those with type 2 diabetes 72 
compared to those with prediabetes (3,4). Thus, different biomarkers of subclinical 73 
inflammation are related to early versus late stages of glycaemic deterioration, but little is 74 
known about the underlying pathophysiology (5).  75 
If subclinical inflammation influences early deterioration of glycaemic control, biomarkers of 76 
subclinical inflammation should be associated with development of prediabetes, when 77 
individuals with NGT are followed-up longitudinally. To date two small studies have failed to 78 
provide evidence for an association of proinflammatory cytokines or adiponectin with 79 
incident IFG or IGT (6,7). An alternative approach with higher statistical power is to 80 
investigate whether baseline levels of biomarkers of subclinical inflammation are associated 81 
with subsequent changes in measures of glucose metabolism (8,9). 82 
In this study, we adopted that latter approach to examine whether biomarkers of subclinical 83 
inflammation are associated with 5-year changes in glucose and insulin levels, HbA1c, insulin 84 
sensitivity and beta-cell function before the diagnosis of type 2 diabetes in a large population-85 
based cohort. The study was based on three 5-year observation cycles, which were combined 86 
by means of a mixed model (10). Since there is evidence for an impact of hyperglycaemia and 87 
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hyperinsulinaemia on subclinical inflammation and hypoadiponectinaemia (11,12), we also 88 
considered a potentially bidirectional relationship by investigating to what extent markers of 89 
glucose metabolism may also be associated with changes in biomarkers of subclinical 90 
inflammation. 91 
 92 
Materials and Methods 93 
Study participants, procedures and measurements  94 
Participants are from the Whitehall II Study, an occupational cohort of 10,308 British civil 95 
servants (6,896 men and 3,412 women aged 35–55 years) of mainly white ethnicity recruited 96 
between 1985 and 1988 (phase 1) (13). The UK NHS Health Research Authority London-97 
Harrow ethics committee reviewed and approved the study. Written informed consent was 98 
obtained from each participant at each examination phase. The study was conducted 99 
according to the principles of the Helsinki Declaration. The cohort has been followed at eight 100 
subsequent phases, 2.5 years apart. All study phases included a questionnaire, and every 101 
second phase (5 years apart) also included a clinical health examination (phases 1, 3, 5, 7, and 102 
9). Phase 3 (1991–1993) was the first phase with an oral glucose tolerance test (OGTT), 103 
therefore phase 1 was not used. In the Whitehall II cohort 8,815 participated at phase 3 104 
(1991–1993); 7,870 at phase 5 (1997–1999); 6,967 at phase 7 (2002–2004); and 6,761 at 105 
phase 9 (2007–2009) with the same individual participating in several phases. During follow-106 
up, participants were censored if they died, were lost to follow-up or developed diabetes. 107 
Anthropometric, demographic, clinical and lifestyle characteristics are summarised in Table 1.  108 
At phases 3, 5, 7, and 9 a standard 2-hour 75 g OGTT was performed in the morning after an 109 
overnight fast (≥8 hours of fasting). For around one third of the examinations, the OGTT was 110 
administered in the afternoon after a light fat-free breakfast (≥5 hours of fasting). These 111 
examinations were not considered in this study. Diabetes was diagnosed by a doctor outside 112 
the study or at screening by OGTT. Screen-detected diabetes was ascertained throughout 113 
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follow-up by OGTTs administered every 5 years and defined according to the OGTT criteria 114 
defined by the World Health Organization (14). 115 
Information on smoking habits (never/ex/current), alcohol consumption (units per week) and 116 
physical activity (hours per week of mild, moderate and vigorous physical activity) were 117 
collected using a self-administered questionnaire (15). 118 
Plasma glucose, serum insulin, HbA1c and serum lipids were measured as described 119 
previously (16,17). Insulin sensitivity and beta-cell function were estimated based on fasting 120 
plasma glucose and serum insulin using the homeostasis model assessment for insulin 121 
resistance (HOMA-IR) and beta-cell function (HOMA-β). In addition, whole-body insulin 122 
sensitivity was assessed using the insulin sensitivity index (ISI0–120) based on fasting and 2-123 
hour values of glucose and insulin (18).  124 
High-sensitivity CRP (hsCRP) was measured using a high-sensitivity immunonephelometric 125 
assay, IL-6 was measured using a high-sensitivity ELISA assay, IL-1 receptor antagonist (IL-126 
1Ra) and total adiponectin were measured with Quantikine ELISA kits (R&D Systems, 127 
Wiesbaden, Germany) in a diabetes case-cohort sample (19,20). 128 
 129 
Statistical analysis  130 
Statistical analyses were performed in R version 3.1.3 (The R Foundation for Statistical 131 
Computing) and SAS version 9.2 (SAS Institute, Cary, NC, USA). 132 
In the main analysis the following outcomes were studied: fasting plasma glucose, 2-hour 133 
plasma glucose, HbA1c, fasting and 2-hour serum insulin, HOMA-IR, HOMA-β and ISI0-120. 134 
We excluded 10,529 (36.5%) person-examinations for which the participant had been fasting 135 
for <8 hours (OGTTs administered in the afternoon). Outcomes with a skewed distribution 136 
(fasting and 2-hour insulin, HOMA-IR, HOMA-β and ISI0-120) were log-transformed prior to 137 
analysis. 138 
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The following biomarkers of subclinical inflammation were included as exposures: high-139 
sensitivity (hs)CRP, IL-6, IL-1 receptor antagonist (IL-1Ra) and adiponectin (all Log2 140 
transformed prior to analysis). As adiponectin and IL-1Ra were measured only in a case-141 
cohort subsample nested within the Whitehall II study (19,20), analyses were restricted to the 142 
subcohort with these measurements. We excluded 412 (2.3%) person-examinations with 143 
hsCRP >10 mg/l as indicator of acute infections.  144 
Up to a total of 17,891 person-examinations for 7,683 non-diabetic participants were analysed 145 
(8,303 person-examinations for 2,965 participants in the subcohort). We studied the 146 
associations of baseline levels of inflammation-related biomarkers and 5-year follow-up 147 
levels of the different outcomes, including the baseline level of the outcome as a covariate. 148 
The main analysis is based on all available data after the aforementioned exclusions and 149 
provides effect estimates per doubling in baseline levels of the respective biomarker. In 150 
addition, we used the subset of the population for whom all four biomarkers were available at 151 
the same time-points to calculate regression coefficients that were standardised per 1-SD 152 
difference in the Log of the biomarker to allow direct comparisons of effect sizes between the 153 
exposure variables.  154 
All analyses were adjusted for age, sex, study phase and baseline value of the outcome 155 
studied (model 1). We further adjusted the analyses for other variables in a successive 156 
manner:  157 
- model 2, further adjustment for baseline BMI;  158 
- model 3, further adjustment for baseline lifestyle factors (smoking, physical activity, alcohol 159 
intake) and lipids (triacylglycerols, HDL-C, LDL-C);  160 
- model 4, further adjustment for 5-year change in BMI after baseline.  161 
To compare the estimated associations across models 1-4 for a given outcome and exposure, 162 
we used a complete-case approach, limiting the analyses to data with complete information on 163 
all covariates in model 4. Except for HbA1c, which was only measured at phases 7 and 9, the 164 
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same individual may contribute with more than one observation to the analyses. To account 165 
for the likely correlation of repeated measurements within the same participant, we used 166 
mixed-effects models with a random intercept and a random slope for time. For HbA1c, a 167 
standard linear model was used. In a sensitivity analysis, we further tested whether the 168 
associations were changed when using waist circumference instead of BMI. 169 
In the reverse approach, we interchanged exposures and outcomes and studied the 170 
associations of the baseline levels of glycaemia, insulin, insulin sensitivity and beta-cell 171 
function with 5-year changes in inflammation-related biomarkers. These analyses were 172 
performed using the same methods and models as described above.  173 
A two-sided 5% level of significance was adjusted for multiple testing with the method of 174 
Benjamini and Hochberg (21). This method controls the false discovery rate and is considered 175 
more powerful than the more simple Bonferroni adjustment of the error rate, because the risk 176 
of false negative results is lower with the Benjamini-Hochberg method. 177 
 178 
Results 179 
Associations between biomarkers of inflammation at baseline and 5-year changes in 180 
glycaemia, insulin, insulin sensitivity and beta-cell functio   181 
Higher systemic concentrations of hsCRP, IL-6 and IL-1Ra were associated with higher 182 
changes in fasting and 2-hour glucose and fasting and 2-hour insulin, but not HbA1c, whereas 183 
adiponectin was inversely associated with all these five outcomes (Table 2, model 1). After 184 
adjustment for baseline BMI, lipids, lifestyle factors and change in BMI, the positive 185 
associations of hsCRP and IL-6 with fasting insulin and the inverse associations between 186 
adiponectin and fasting glucose, HbA1c and fasting insulin remained significant (Table 2, 187 
models 2-4). 188 
High baseline levels of hsCRP, IL-6 and IL-1Ra were also associated with increases in insulin 189 
resistance (i.e. increase in HOMA-IR and decrease in ISI0,120) and beta-cell function, while 190 
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baseline adiponectin showed inverse associations (Table 2, model 1). Effect sizes were 191 
attenuated by adjustment for the aforementioned covariables, but the associations of hsCRP, 192 
IL-6 and adiponectin with changes in HOMA-IR and the associations of IL-6 and adiponectin 193 
with HOMA-β remained significant in the final model (model 4). Associations with ISI0,120 194 
lost statistical significance after adjustment. 195 
To compare effect sizes between exposures, we standardised our estimates per 1 population 196 
SD of one Log unit of the concentrations of the four biomarkers of subclinical inflammation 197 
(Fig. 1;  Supplementary Tables 1 and 2). Effect sizes were similar for hsCRP, IL-6 and IL-198 
1Ra, but of larger magnitude (and in the opposite direction) for adiponectin. 199 
We substituted BMI with waist circumference in a sensitivity analysis. In general this 200 
changed little (<10%) of the effect estimates in Table 2 (data not shown). Some effect 201 
estimates showed greater changes (≥10%), but these were only observed for non-significant 202 
associations.  203 
 204 
Associations of glycaemia, insulin, insulin sensitivity and beta-cell function at baseline 205 
with 5-year changes in biomarkers of inflammation 206 
When interchanging exposures and outcomes, we observed fewer significant associations 207 
(Fig. 2). None of the measures of glycaemia was associated with changes in hsCRP, IL-6, IL-208 
1Ra or adiponectin when further adjusting for 5-year change in BMI after baseline (fully 209 
adjusted model), except an inverse association between 2-hr glucose and IL-1Ra 210 
(Supplementary Tables 3 and 4). Fasting insulin and HOMA-IR showed inverse associations 211 
with changes in adiponectin in the fully adjusted models, but neither insulin levels nor 212 
HOMA-IR were related to changes in hsCRP, IL-6 or IL-1Ra (Supplementary Tables 3 and 213 
4). High baseline levels of ISI0,120 were positively associated with increases in IL-1Ra 214 
(Supplementary Tables 3 and 4).  215 
 216 
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Discussion 217 
This study examined the temporal relationship between biomarkers of subclinical 218 
inflammation and changes in glucose metabolism before the diagnosis of type 2 diabetes 219 
using repeat data. Baseline levels of hsCRP and IL-6 were positively associated with 220 
subsequent increases in fasting insulin, HOMA-IR and beta-cell function, while adiponectin 221 
was inversely associated with future changes in fasting glucose, HbA1c, fasting insulin, 222 
HOMA-IR and beta-cell function. In the reverse analysis, baseline fasting insulin and 223 
HOMA-IR were associated with decreases in adiponectin, while 2-hour glucose and ISI0,120 224 
showed associations with changes in IL-1Ra. 225 
 226 
Subclinical inflammation and glycaemia  227 
Serum hsCRP, IL-6 and IL-1Ra were associated with 5-year increases in fasting and 2-hour 228 
glucose in age and sex-adjusted models, but further adjustment attenuated these associations 229 
to non-significance with BMI being the most important confounder. In contrast, adiponectin 230 
levels showed an independent inverse association with fasting glucose, but not with 2-hour 231 
glucose. These data are novel and may point towards a specific role of adiponectin in the early 232 
deterioration of glycaemia.  233 
Fasting glucose levels are mainly determined by hepatic glucose production, whereas 234 
increased 2-hour glucose mainly reflects peripheral glucose uptake (22). Adiponectin 235 
receptors (ADIPOR)-1 and 2 are expressed on both hepatocytes and skeletal muscle cells with 236 
ADIPOR2 being the predominant receptor in the liver and ADIPOR1 the predominant 237 
receptor in skeletal muscle (23). Therefore, it can be speculated that ADIPOR2-mediated 238 
signaling and downstream effects on peroxisome proliferator-activated receptor-α and 239 
regulation of glucose uptake, fatty acid oxidation, oxidative stress and inflammation may 240 
mediate the observed association between adiponectin and deterioration of fasting glycaemia 241 
in our study. Importantly, chronically decreased adiponectin levels are indicators of adipose 242 
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tissue dysfunction and not only related to increased risk of type 2 diabetes, but also to diabetic 243 
complications (1,2,24,25).  244 
With respect to HbA1c, we observed an inverse association between adiponectin and increases 245 
in HbA1c, but no associations of the other three biomarkers. Based on the findings for fasting 246 
glucose, associations may have been expected for all four biomarkers at least for the age and 247 
sex-adjusted model. However, this discrepancy may be due to the fact that glucose levels are 248 
only weak determinants of HbA1c in non-diabetic individuals (26). Furthermore, the sample 249 
size for the HbA1c analysis was smaller than that for other glycaemic traits. Our data are only 250 
partly in line with previous observations in the KORA study showing a positive association 251 
between hsCRP and 7-year changes in HbA1c, but no association between adiponectin and 252 
HbA1c (9). There are no obvious differences in baseline characteristics between the two 253 
studies, so the relevance of subclinical inflammation for HbA1c levels in non-diabetic 254 
individuals merits further studies.   255 
 256 
Subclinical inflammation and insulin resistance 257 
Our study revealed consistent associations between all four biomarkers and fasting insulin and 258 
HOMA-IR, although the associations of IL-1Ra were not i dependent of 5-year changes in 259 
BMI. In contrast, for 2-hour insulin and IS0-120, which were based on post-load measures, 260 
associations with hsCRP, IL-6 and adiponectin were only found in the initial regression 261 
models, but not after full adjustment.    262 
So far, only one previous study employed a comparable design and found that high hsCRP 263 
levels were associated with increases in HOMA-IR in a young non-diabetic population (8). 264 
Thus, the use of a more comprehensive assessment of subclinical inflammation and dynamic 265 
measures of insulin resistance represents an extension of the current literature. Our 266 
observations for changes in fasting insulin and HOMA-IR complemented and corroborated 267 
our findings for fasting glucose and pointed towards an association between subclinical 268 
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inflammation and hepatic rather than peripheral insulin resistance in non-diabetic individuals. 269 
Associations were weaker for changes in IL-1Ra. IL-1Ra levels are considered as indicators 270 
of IL-1β-mediated processes. IL-1β has been demonstrated to induce insulin resistance in 271 
hepatocytes (27). Therefore, an association between IL-1Ra and hepatic insulin resistance is 272 
plausible. 273 
 274 
Subclinical inflammation and beta-cell function 275 
This is apparently the first study to show that higher hsCRP, IL-6 and IL-1Ra and lower 276 
adiponectin at baseline are associated with 5-year increases in beta-cell function assessed in 277 
the fasting state. After full adjustment, high IL-6 levels and low adiponectin levels remained 278 
associated with increases in fasting beta-cell function.  279 
Although an increase in beta-cell function does not seem intuitively related to an increased 280 
risk of type 2 diabetes, our findings have to be seen in context of the aforementioned 281 
associations with worsening fasting glycaemia and increased insulin resistance. The 282 
associations of IL-6 and adiponectin with increases in beta-cell function were most likely a 283 
consequence of their associations with increased insulin resistance. In other words, increases 284 
in HOMA-IR in our non-diabetic study sample may reflect a compensatory upregulation of 285 
insulin secretion in response to decreases in insulin action, which was still sufficient to 286 
maintain glucose levels.  287 
However, our data are also in line with the alternative hypothesis that biomarkers of 288 
subclinical inflammation have a direct impact on beta-cell function. At least IL-6 has been 289 
reported to stimulate insulin secretion through an incretin-mediated mechanism in 290 
experimental models of diabetes (28). The interpretation of our findings regarding beta-cell 291 
function would have been facilitated by the investigation of associations between subclinical 292 
inflammation and changes in the disposition index. Unfortunately, the assessment of dynamic 293 
beta-cell function is not possible with the available data in the Whitehall II cohort. 294 
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 295 
Bidirectionality in temporal associations between subclinical inflammation and markers 296 
of glucose metabolism 297 
Our study is unique because our design allowed us to assess the potential bidirectionality in 298 
the associations of subclinical inflammation and glucose metabolism. Reversing our initial 299 
analysis led to two main results: First, fasting insulin and HOMA-IR were associated with 300 
decreases in adiponectin. Second, 2-hour glucose showed inverse and ISI0-120 showed direct 301 
associations with changes in IL-1Ra.  302 
It has been proposed that hypoadiponectinaemia in obesity and type 2 diabetes may be a 303 
consequence rather than a cause of insulin resistance (12). The regulation of adiponectin is 304 
still poorly understood in humans, so we cannot draw firm conclusions. However, the results 305 
are consistent with our previous observations of continuous and faster decrease in adiponectin 306 
levels preceding the development of type 2 diabetes compared to healthy adults (20). Our 307 
study suggests that adiponectin and insulin resistance are linked in a bidirectional way with 308 
potential deleterious consequences for the regulation of glucose metabolism. 309 
The associations between 2-hour glucose, ISI0-120 and changes in IL-1Ra point towards a 310 
potential link between peripheral insulin action and regulation of IL-1Ra. Such a link is 311 
plausible given the fact that the release of both IL-1β and IL-1Ra after exercise is part of 312 
normal skeletal muscle physiology (29). However, it is currently unclear how impairments in 313 
muscle insulin sensitivity could influence circulating levels of both proteins. 314 
From a pathophysiological point-of-view, any bidirectionality in the relationship between 315 
subclinical inflammation and insulin resistance could reflect a positive feed-back loop, 316 
potentially fueling a vicious cycle resulting in progressive worsening of glycaemic control. 317 
Our finding of a limited degree of bidirectionality consequently argues in favour of a 318 
deleterious impact of hypoadiponectinaemia and subclinical inflammation in the development 319 
of dysglycaemia.  320 
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 321 
Strengths and limitations 322 
Strengths of our study are its large sample size and the analysis of quantitative traits entailing 323 
a larger statistical power than the analysis of a dichotomous outcome (e.g. prediabetes). 324 
Further strengths are the use of multiple measures of glucose metabolism reflecting different 325 
pathophysiological aspects and the availability of repeat data from up to four study phases, 326 
which allowed us to assess potential bidirectional relationships. Moreover, we adjusted for 327 
baseline BMI and its 5-year changes and thus demonstrated that associations were not solely 328 
mediated by obesity. 329 
One limitation is the observational design that provides evidence for temporal, but not for 330 
causal relationships. Moreover, HOMA-IR and ISI0-120 correlate only moderately well with 331 
the euglycaemic-hyperinsulinaemic clamp (30), but clamp measurements were not available. 332 
Thus, our assessment of insulin resistance was less precise than the gold standard, and we had 333 
to rely on indirect estimates to compare hepatic versus peripheral insulin resistance. HOMA-β 334 
can only be used to estimate fasting beta-cell function, and our study did not include dynamic 335 
assessments of beta-cell function. This limits the precision of the measurmenent, and we 336 
could not examine beta-cell function relative to insulin sensitivity using the disposition index. 337 
We used a complete case approach in our analyses. The fraction of missingness of hsCRP and 338 
IL-6 in the cohort was around 5% and between 10-15% for IL-1Ra and adiponectin in the 339 
subcohort. Therefore, and because we are studying associations, the effect of any potential 340 
non-randomness of the missing data for biomarkers of subclinical inflammation is considered 341 
negligible. 342 
A final limitation of our study is the selection of four biomarkers, which left out others that 343 
also merit further research. We focused on hsCRP, IL-6, IL-1Ra and adiponectin as pro- and 344 
anti-inflammatory biomarkers because of their well established associations with incident 345 
type 2 diabetes in prospective studies (1,2,31). Based on experimental data and other 346 
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epidemiological studies, cytokines such as IL-1β (32-34), tumour necrosis factor (TNF)-α 347 
(35,36) and transforming growth factor (TGF)-β (37,38) and chemokines such as monocyte 348 
chemoattractant protein-1/chemokine (C-C motif) ligand 2 (MCP-1/CCL2) (39,40) 349 
undoubtedly represent interesting candidates because of their impact on insulin sensitivity 350 
and/or beta-cell function. However, circulating levels of IL-1β are below the limit of detection 351 
for a large proportion of individuals in population-based studies with currently available 352 
assays, and experimental data on TNFα and insulin resistance do not appear to be translated 353 
into an association between circulating levels of this protein and risk of type 2 diabetes in 354 
cohort studies (41,42). Data on most other inflammation-related biomarkers and incident type 355 
2 diabetes are based on only one or very few cohorts, so that further studies on their relevance 356 
both for early deterioration of glucose metabolism and for the manifestation of type 2 diabetes 357 
would be important.  358 
 359 
Conclusion 360 
Our study demonstrates multiple associations between baseline levels of biomarkers of 361 
subclinical inflammation and subsequent 5-year changes in glycaemia, insulin resistance and 362 
beta-cell function in a large population-based cohort of on-diabetic individuals. These 363 
findings are consistent with the hypothesis that subclinical inflammation may increase hepatic 364 
insulin resistance and upregulate beta-cell function. We observed less consistent evidence for 365 
a bidirectionality in these temporal relationships, suggesting that low-grade inflammation 366 
precedes insulin resistance rather than vice versa. 367 
 368 
 369 
 370 
  371 
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Figure 1 Effect of one population standard deviation difference in the Log of the immune 543 
marker at baseline (hsCRP, IL-6, IL-1RA, adiponectin) on subsequent 5-year changes in 544 
markers of glucose regulation. The associations are adjusted for baseline age, sex, study 545 
phase, BMI, smoking, physical activity, alcohol intake, triacylglycerols, HDL-C and LDL-C 546 
and baseline value of the outcome. 547 
 548 
Figure 2 Effect of a difference in baseline glycaemia, insulin sensitivity or beta-cell function 549 
on subsequent 5-year changes in immune markers (hsCRP, IL-6, IL-1RA, adiponectin). The 550 
associations are adjusted for baseline age, sex, study phase, BMI, smoking, physical activity, 551 
alcohol intake, triacylglycerols, HDL-C and LDL-C and baseline value of the outcome. 552 
 553 
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Table 1 Characteristics of the study population at each study phase 1 
 Variable 
Phase 3 (1991-
1993) 
Phase 5 (1997-
1999) 
Phase 7 (2002-
2004) 
Phase 9 (2007-
2009) 
n 5310 4310 4498 3773 
Men (%) 69.1 (67.8;70.3) 71.6 (70.3;73.0) 73.3 (71.9;74.5) 72.9 (71.4;74.3) 
White ethnicity (%) 90.5 (89.7;91.3) 91.9 (91.1;92.7) 92.8 (92.0;93.5) 93.1 (92.2;93.8) 
Age (years) 49.4 (6.0) 55.1 (5.9) 60.6 (5.9) 65.4 (5.9) 
BMI (kg/m
2
) 25.3 (3.7) 26.1 (3.9) 26.6 (4.2) 26.6 (4.3) 
Waist circumference (cm) 85.7 (11.6) 90.5 (11.6) 93.3 (11.9) 94.4 (11.9) 
Total cholesterol (mmol/l) 6.5 (1.2) 5.9 (1.1) 5.8 (1.0) 5.3 (1.1) 
HDL cholesterol (mmol/l) 1.4 (0.4) 1.5 (0.4) 1.6 (0.4) 1.6 (0.4) 
LDL cholesterol (mmol/l) 4.4 (1.0) 3.9 (0.9) 3.6 (0.9) 3.2 (1.0) 
Triacylglycerols (mmol/l) 1.5 (1.1) 1.3 (0.9) 1.3 (0.9) 1.2 (0.7) 
Systolic blood pressure (mmHg) 120.4 (13.6) 122.2 (16.3) 127.7 (16.8) 125.3 (15.9) 
Diastolic blood pressure (mmHg) 79.7 (9.5) 77.3 (10.4) 74.5 (10.5) 71.5 (10.0) 
Fasting plasma glucose (mmol/l) 5.3 (0.7) 5.2 (0.7) 5.3 (0.8) 5.2 (0.6) 
2-hour plasma glucose (mmol/l) 5.3 (1.9) 5.9 (1.8) 6.3 (1.9) 6.4 (1.9) 
HbA1c (%) - - 5.3 (0.5) 5.6 (0.4) 
HbA1c (mmol/mol) - - 39.1 (5.9) 43.8 (5.3) 
Fasting serum insulin (pmol/l) 5.7 (3.7;8.9) 7.0 (4.9;10.2) 7.0 (4.7;10.7) 6.6 (4.3;10.2) 
2-hour serum insulin (pmol/l) 33.0 (18.5;56.5) 32.6 (19.8;53.2) 37.8 (23.3;63.7) 41.3 (25.6;69.1) 
HOMA-IR 1.3 (0.8;2.1) 1.6 (1.1;2.4) 1.6 (1.1;2.6) 1.5 (1.0;2.4) 
HOMA-β 67.1 (44.4;100.8) 92.0 (65.1;131.3) 80.0 (55.2;118.9) 82.2 (55.7;120) 
ISI0-120 40.7 (31.5;53.3) 38.1 (29.8;48.9) 34.4 (26.4;44.5) 33.6 (25.5;43.6) 
hsCRP (mg/dl) 0.9 (0.4;1.8) 1.0 (0.5;2.0) 1.2 (0.6;2.4) - 
IL-6 (pg/ml) 1.4 (1.0;2.0) 1.4 (1.0;2.0) 1.7 (1.2;2.4) - 
IL-1Ra (pg/ml)
a
 0.2 (0.2;0.3) 0.3 (0.3;0.4) 0.3 (0.3;0.4) 0.3 (0.3;0.4) 
Adiponectin (µg/ml)
a
 8.7 (6.4;12.4) 8.6 (6.2;12.2) 8.3 (6.0;11.7) 8.5 (5.6;13.4) 
Family history of diabetes (%) 11.2 (10.4;12.1) 10.3 (9.4;11.3) 10.0 (9.1;10.9) 9.6 (8.7;10.6) 
Current smoker (%) 13.7 (12.8;14.7) 10.4 (9.5;11.3) 8.4 (7.6;9.3) 5.7 (5.0;6.5) 
Moderate to vigorous exercise (hours/week) 2.0 (1.0;5.0) 11.5 (4.5;20.0) 12.0 (4.5;20.5) - 
Alcohol intake (units/week) 6.0 (2.0;14.0) 10.0 (3.0;20.0) 9.0 (3.0;18.0) 7.0 (2.0;16.0) 
Antihypertensive treatment (%) 7.3 (6.6;8.0) 11.3 (10.3;12.2) 22.2 (21;23.4) 33.0 (31.5;34.5) 
Lipid-lowering treatment (%) 0.8 (0.6;1.1) 2.8 (2.4;3.4) 10.0 (9.2;11.0) 29.1 (27.6;30.6) 
 2 
Data are means (SD), medians (25
th
;75
th
 percentiles) or proportions (95% CI). 3 
a
Subsample (n=2636). 4 
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Table 2 Effects (with 95% CI) of a doubling in the inflammatory marker at baseline on 5-year changes in glycaemia, insulin, insulin sensitivity and 1 
beta-cell function  2 
  hsCRP IL-6 IL-1Ra Adiponectin 
Outcome Model n Estimate P n Estimate P n Estimate P n Estimate P 
Fasting glucose 
(mmol/l) 1 6716 0.02 (0.01;0.03) <0.001 6525 0.02 (0.00;0.04) 0.027 3651 0.05 (0.02;0.08) 0.004 3651 -0.05 (-0.08;-0.02) <0.001 
 2 6716 0.01 (0.00;0.02) 0.044 6525 0.01 (-0.01;0.03) 0.336 3651 0.03 (-0.01;0.06) 0.132 3651 -0.04 (-0.07;-0.01) 0.003 
 3 6716 0.01 (0.00;0.02) 0.139 6525 0.00 (-0.02;0.02) 0.778 3651 0.02 (-0.02;0.05) 0.353 3651 -0.04 (-0.07;-0.01) 0.020 
 4 6716 0.01 (0.00;0.02) 0.208 6525 0.00 (-0.02;0.02) 0.968 3651 0.01 (-0.03;0.05) 0.591 3651 -0.04 (-0.07;-0.01) 0.011 
2-h glucose 
(mmol/l) 1 6033 0.08 (0.05;0.10) <0.001 6029 0.08 (0.03;0.13) 0.003 3479 0.11 (0.01;0.20) 0.027 3479 -0.13 (-0.21;-0.05) 0.001 
 2 6033 0.04 (0.01;0.07) 0.004 6029 0.03 (-0.02;0.08) 0.292 3479 0.00 (-0.10;0.10) 0.998 3479 -0.09 (-0.17;-0.01) 0.035 
 3 6033 0.03 (0.00;0.06) 0.028 6029 0.01 (-0.04;0.07) 0.661 3479 -0.03 (-0.14;0.07) 0.509 3479 -0.07 (-0.16;0.02) 0.135 
 4 6033 0.03 (0.00;0.06) 0.044 6029 0.01 (-0.05;0.06) 0.806 3479 -0.05 (-0.16;0.05) 0.309 3479 -0.07 (-0.16;0.02) 0.109 
HbA1c 
(mmol/mol) 1 2535 0.06 (-0.05;0.16) 0.285 2363 -0.11 (-0.31;0.08) 0.263 1190 -0.01 (-0.42;0.40) 0.961 1190 -0.53 (-0.88;-0.18) 0.003 
 2 2535 0.02 (-0.09;0.14) 0.712 2363 -0.16 (-0.36;0.04) 0.120 1190 -0.10 (-0.55;0.34) 0.648 1190 -0.52 (-0.88;-0.16) 0.005 
 3 2535 0.01 (-0.11;0.12) 0.904 2363 -0.17 (-0.38;0.04) 0.107 1190 -0.23 (-0.69;0.23) 0.325 1190 -0.45 (-0.84;-0.06) 0.026 
 4 2535 -0.01 (-0.12;0.11) 0.874 2363 -0.22 (-0.42;-0.02) 0.033 1190 -0.28 (-0.73;0.18) 0.238 1190 -0.44 (-0.83;-0.05) 0.028 
Fasting insulin 
(% diff.) 1 6186 2.5 (1.7;3.3) <0.001 6177 4.8 (3.2;6.4) <0.001 3617 7.2 (4.3;10.2) <0.001 3617 -5.6 (-7.8;-3.3) <0.001 
 2 6186 1.4 (0.6;2.3) 0.001 6177 3.4 (1.8;5.0) <0.001 3617 4.9 (1.9;7.9) 0.001 3617 -4.8 (-7.0;-2.6) <0.001 
 3 6186 1.1 (0.3;2.0) 0.010 6177 2.7 (1.2;4.4) <0.001 3617 4.0 (1.0;7.1) 0.009 3617 -4.1 (-6.5;-1.7) 0.001 
 4 6186 0.9 (0.1;1.7) 0.024 6177 2.2 (0.7;3.7) 0.003 3617 2.4 (-0.4;5.3) 0.094 3617 -4.6 (-6.8;-2.3) <0.001 
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2-h insulin (% 
diff.) 1 5951 2.4 (1.3;3.5) <0.001 5946 2.5 (0.4;4.8) 0.021 3428 4.0 (0.0;8.1) 0.050 3428 -5.1 (-8.2;-1.8) 0.002 
 2 5951 1.7 (0.5;3.0) 0.005 5946 1.5 (-0.7;3.8) 0.188 3428 2.0 (-2.2;6.4) 0.349 3428 -4.4 (-7.6;-1.1) 0.010 
 3 5951 1.4 (0.2;2.6) 0.028 5946 0.9 (-1.4;3.2) 0.457 3428 1.0 (-3.3;5.4) 0.667 3428 -3.8 (-7.2;-0.2) 0.038 
 4 5951 1.2 (0.0;2.4) 0.057 5946 0.5 (-1.7;2.7) 0.681 3428 -0.6 (-4.7;3.7) 0.791 3428 -4.0 (-7.4;-0.6) 0.024 
HOMA-IR (% 
diff.) 
1 6168 2.7 (1.8;3.6) <0.001 6159 5.0 (3.3;6.7) <0.001 3612 7.9 (4.7;11.1) <0.001 3612 -6.2 (-8.6;-3.8) <0.001 
 2 6168 1.5 (0.6;2.5) 0.001 6159 3.5 (1.8;5.2) <0.001 3612 5.3 (2.1;8.7) 0.001 3612 -5.4 (-7.8;-3.0) <0.001 
 3 6168 1.2 (0.3;2.2) 0.010 6159 2.7 (1.0;4.5) 0.002 3612 4.3 (1.0;7.7) 0.010 3612 -4.6 (-7.2;-2.0) <0.001 
 4 6168 1.0 (0.1;1.9) 0.025 6159 2.2 (0.6;3.8) 0.008 3612 2.6 (-0.5;5.7) 0.096 3612 -5.2 (-7.5;-2.7) <0.001 
HOMA-β (% 
diff.) 
1 6164 2.1 (1.3;2.9) <0.001 6155 4.3 (2.7;5.8) <0.001 3611 5.3 (2.5;8.2) <0.001 3611 -3.9 (-6.1;-1.7) <0.001 
 2 6164 1.1 (0.3;2.0) 0.009 6155 3.0 (1.5;4.6) <0.001 3611 3.7 (0.8;6.7) 0.012 3611 -3.3 (-5.5;-1.0) 0.005 
 3 6164 1.0 (0.1;1.8) 0.031 6155 2.6 (1.0;4.2) 0.001 3611 3.2 (0.2;6.3) 0.036 3611 -2.7 (-5.0;-0.2) 0.032 
 4 6164 0.8 (0.0;1.6) 0.064 6155 2.2 (0.7;3.8) 0.005 3611 2.0 (-0.8;5.0) 0.163 3611 -3.0 (-5.3;-0.7) 0.012 
ISI0-120 (% 
diff.) 
1 5800 -1.6 (-2.2;-1.0) <0.001 5793 -1.9 (-3.1;-0.8) <0.001 3419 -2.5 (-4.5;-0.5) 0.015 3419 2.9 (1.1;4.7) 0.002 
 2 5800 -1.0 (-1.6;-0.3) 0.003 5793 -1.0 (-2.2;0.2) 0.090 3419 -0.6 (-2.8;1.6) 0.596 3419 2.1 (0.3;4.0) 0.023 
 3 5800 -0.8 (-1.4;-0.1) 0.022 5793 -0.6 (-1.8;0.6) 0.320 3419 0.0 (-2.2;2.4) 0.970 3419 1.8 (-0.2;3.7) 0.075 
 4 5800 -0.7 (-1.3;0.0) 0.046 5793 -0.4 (-1.6;0.8) 0.519 3419 0.9 (-1.4;3.1) 0.457 3419 1.9 (0.0;3.9) 0.049 
 3 
n: number of person-examinations used in the particular analysis. P: P value for the test of the effect being equal to zero. Values in bold print 4 
indicate significant associations after adjustment for multiple testing (128 tests) with the method of Benjamini and Hochberg. 5 
Model 1: Adjusted for baseline age, sex, study phase and baseline value of the outcome.  6 
Model 2: Further adjustment for baseline BMI.  7 
Model 3: Further adjustment for baseline smoking, physical activity, alcohol intake, triacylglycerols, HDL-C and LDL-C.  8 
Model 4: Further adjustment for 5-year change in BMI after baseline. 9 
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Supplementary Table 1 Effects (with 95% CI) of a standard deviation increase in Log of the inflammatory marker at baseline on 5-year changes in 
glycaemia and insulin. 
 
  hsCRP  IL-6  IL-1Ra  Adiponectin 
Outcome Model n Estimate P  n Estimate P  n Estimate P  n Estimate P 
Fasting plasma 
glucose (mmol/l) 1 3589 0.03 (0.01;0.05) 0.004  3589 0.02 (0.00;0.04) 0.036  3589 0.03 (0.01;0.05) 0.005  3589 -0.04 (-0.06;-0.02) <0.001 
 2 3589 0.02 (-0.01;0.04) 0.143  3589 0.01 (-0.01;0.03) 0.264  3589 0.02 (-0.01;0.04) 0.160  3589 -0.03 (-0.05;-0.01) 0.004 
 3 3589 0.01 (-0.01;0.03) 0.274  3589 0.01 (-0.02;0.03) 0.572  3589 0.01 (-0.01;0.03) 0.406  3589 -0.03 (-0.05;0.00) 0.020 
 4 3589 0.01 (-0.01;0.03) 0.326  3589 0.00 (-0.02;0.03) 0.670  3589 0.01 (-0.02;0.03) 0.640  3589 -0.03 (-0.05;-0.01) 0.011 
2-hour plasma 
glucose (mmol/l) 1 3421 0.08 (0.02;0.13) 0.005  3421 0.08 (0.02;0.14) 0.006  3421 0.07 (0.01;0.12) 0.028  3421 -0.09 (-0.16;-0.03) 0.003 
 2 3421 0.02 (-0.04;0.08) 0.468  3421 0.04 (-0.02;0.10) 0.169  3421 0.00 (-0.06;0.06) 0.959  3421 -0.06 (-0.12;0.00) 0.058 
 3 3421 0.00 (-0.06;0.06) 0.981  3421 0.02 (-0.04;0.09) 0.452  3421 -0.02 (-0.09;0.04) 0.541  3421 -0.04 (-0.11;0.02) 0.205 
 4 3421 -0.01 (-0.07;0.05) 0.853  3421 0.02 (-0.04;0.08) 0.512  3421 -0.03 (-0.10;0.03) 0.343  3421 -0.05 (-0.11;0.02) 0.166 
HbA1c (mmol/mol) 1 1184 0.10 (-0.17;0.37) 0.463  1184 -0.13 (-0.4;0.14) 0.335  1184 -0.02 (-0.27;0.24) 0.889  1184 -0.40 (-0.67;-0.14) 0.003 
 2 1184 0.06 (-0.23;0.35) 0.681  1184 -0.20 (-0.48;0.09) 0.178  1184 -0.08 (-0.36;0.20) 0.574  1184 -0.40 (-0.67;-0.12) 0.005 
 3 1184 0.04 (-0.25;0.34) 0.780  1184 -0.20(-0.49;0.09) 0.183  1184 -0.16 (-0.45;0.13) 0.282  1184 -0.34 (-0.64;-0.04) 0.025 
 4 1184 0.03 (-0.27;0.32) 0.860  1184 -0.24 (-0.53;0.05) 0.102  1184 -0.18 (-0.47;0.10) 0.213  1184 -0.33 (-0.63;-0.04) 0.028 
Fasting insulin (% 
diff.) 1 3555 3.2 (1.6;4.9) <0.001  3555 3.8 (2.1;5.6) <0.001  3555 4.2 (2.5;6.0) <0.001  3555 -4.2 (-5.9;-2.5) <0.001 
 2 3555 1.8 (0.0;3.5) 0.046  3555 2.8 (1.0;4.6) 0.002  3555 2.8 (0.9;4.7) 0.003  3555 -3.6 (-5.4;-1.9) <0.001 
 3 3555 1.6 (-0.2;3.4) 0.083  3555 2.3 (0.5;4.1) 0.012  3555 2.3 (0.4;4.2) 0.018  3555 -3.1 (-5.0;-1.2) 0.001 
 4 3555 1.3 (-0.4;2.9) 0.136  3555 2.0 (0.3;3.7) 0.021  3555 1.3 (-0.4;3.1) 0.138  3555 -3.5 (-5.2;-1.7) <0.001 
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2-hour insulin (% 
diff.) 1 3371 2.8 (0.5;5.2) 0.018  3371 2.6 (0.1;5.2) 0.039  3371 2.5 (0.0;5.0) 0.048  3371 -3.9 (-6.3;-1.4) 0.003 
 2 3371 1.8 (-0.7;4.3) 0.170  3371 1.8 (-0.7;4.4) 0.167  3371 1.3 (-1.4;4.0) 0.344  3371 -3.3 (-5.8;-0.8) 0.011 
 3 3371 1.1 (-1.4;3.7) 0.400  3371 1.1 (-1.5;3.8) 0.395  3371 0.6 (-2.1;3.4) 0.654  3371 -2.9 (-5.6;-0.2) 0.037 
 4 3371 0.7 (-1.8;3.3) 0.579  3371 0.9 (-1.6;3.5) 0.501  3371 -0.3 (-2.9;2.4) 0.840  3371 -3.1 (-5.7;-0.5) 0.022 
 
n: the number of person-examinations used in the particular analysis. P: P value for the test of the effect being equal to zero. Values in bold print 
indicate significant associations after adjustment for multiple testing (128 tests) with the method of Benjamini and Hochberg.  
Model 1: adjusted for baseline age, sex, study phase and baseline value of the outcome 
Model 2: further adjustment for baseline BMI 
Model 3: further adjustment for baseline smoking, physical activity, alcohol intake, triacylglycerols, HDL-C and LDL-C 
Model 4: further adjustment for 5-year change in BMI after baseline 
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Supplementary Table 2 Effects (with 95% CI) of a standard deviation increase in Log of the inflammatory marker at baseline on 5-year changes in 
insulin sensitivity and beta-cell function . 
  hsCRP  IL-6  IL-1Ra  Adiponectin 
Outcome Model n Estimate P  n Estimate P  n Estimate P  n Estimate P 
HOMA-IR (% diff.) 1 3550 3.6 (1.8;5.4) <0.001  3550 4.2 (2.2;6.1) <0.001  3550 4.6 (2.7;6.6) <0.001  3550 -4.7 (-6.5;-2.8) <0.001 
 2 3550 2.0 (0.1;3.9) 0.040  3550 3.0 (1.1;5.0) 0.002  3550 3.0 (1.0;5.1) 0.003  3550 -4.1 (-5.9;-2.2) <0.001 
 3 3550 1.7 (-0.2;3.7) 0.078  3550 2.4 (0.5;4.4) 0.015  3550 2.4 (0.4;4.5) 0.019  3550 -3.5 (-5.5;-1.5) <0.001 
 4 3550 1.4 (-0.4;3.2) 0.133  3550 2.1 (0.2;3.9) 0.027  3550 1.4 (-0.5;3.4) 0.141  3550 -3.9 (-5.8;-2.0) <0.001 
HOMA-β (% diff.) 1 3549 2.2 (0.6;3.9) 0.008  3549 2.8 (1.1;4.5) 0.001  3549 3.1 (1.4;4.9) <0.001  3549 -2.9 (-4.6;-1.2) 0.001 
 2 3549 1.2 (-0.6;2.9) 0.186  3549 2.0 (0.3;3.8) 0.022  3549 2.1 (0.3;4.0) 0.021  3549 -2.4 (-4.2;-0.7) 0.006 
 3 3549 1.1 (-0.6;2.9) 0.218  3549 1.8 (0.0;3.6) 0.049  3549 1.8 (0.0;3.7) 0.055  3549 -2.0 (-3.8;-0.1) 0.039 
 4 3549 0.9 (-0.8;2.6) 0.311  3549 1.5 (-0.2;3.3) 0.076  3549 1.2 (-0.6;3.0) 0.209  3549 -2.3 (-4.0;-0.4) 0.015 
ISI0-120 (% diff.) 1 3363 -1.8 (-3.0;-0.6) 0.003  3363 -1.9 (-3.2;-0.7) 0.003  3363 -1.6 (-2.8;-0.3) 0.016  3363 2.1 (0.7;3.5) 0.003 
 2 3363 -0.7 (-2.0;0.6) 0.264  3363 -1.2 (-2.5;0.1) 0.080  3363 -0.4 (-1.8;1.0) 0.592  3363 1.5 (0.1;2.9) 0.030 
 3 3363 -0.3 (-1.7;1.0) 0.631  3363 -0.8 (-2.1;0.6) 0.273  3363 0.0 (-1.4;1.4) 0.987  3363 1.3 (-0.2;2.8) 0.090 
 4 3363 -0.1 (-1.4;1.2) 0.853  3363 -0.6 (-1.9;0.7) 0.359  3363 0.5 (-0.9;1.9) 0.494  3363 1.4 (0.0;2.9) 0.058 
 
n: the number of person-examinations used in the particular analysis. P: P value for the test of the effect being equal to zero. Values in bold print 
indicate significant associations after adjustment for multiple testing (128 tests) with the method of Benjamini and Hochberg. 
Model 1: adjusted for baseline age, sex, study phase and baseline value of the outcome 
Model 2: further adjustment for baseline BMI 
Model 3: further adjustment for baseline smoking, physical activity, alcohol intake, triacylglycerols, HDL-C and LDL-C 
Model 4: further adjustment for 5-year change in BMI after baseline 
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Supplementary Table 3 Effects (with 95% CI) of a difference in glycaemia and insulin on 5-year changes in the inflammatory marker (% 
difference)  
 
  Fasting plasma glucose (mmol/l)  2-hour plasma glucose (mmol/l)  HbA1c (mmol/mol)  Fasting insulin (doubling)  2-hour insulin (doubling) 
Outcome Model n Estimate P n Estimate P n Estimate P n Estimate P n Estimate P 
hsCRP (% diff.) 1 4043 2.0 (-3.1;7.3) 0.457 3954 0.3 (-1.4;2.1) 0.707 
 
NA 
  
3919 4.6 (1.7;7.7) 0.002 3911 1.2 (-0.9;3.3) 0.270 
2 4043 -1.2 (-6.1;4.1) 0.658 3954 -0.3 (-2.0;1.5) 0.760 
 
NA 
  
3919 0.9 (-2.3;4.1) 0.587 3911 -0.3 (-2.4;1.8) 0.767 
3 4043 -0.6 (-5.6;4.7) 0.823 3954 -0.1 (-1.8;1.7) 0.937 
 
NA 
  
3919 1.0 (-2.3;4.4) 0.550 3911 -0.1 (-2.2;2.1) 0.944 
4 4043 -0.2 (-5.1;4.9) 0.944 3954 0.4 (-1.3;2.1) 0.659 
 
NA 
  
3919 1.3 (-1.9;4.5) 0.443 3911 0.4 (-1.7;2.5) 0.738 
IL-6 (% diff.) 1 3946 0.7 (-2.3;3.9) 0.637 3867 0.3 (-0.7;1.4) 0.559 
 
NA 
  
3821 4.3 (2.5;6.1) <0.001 3828 1.3 (0.0;2.5) 0.045 
2 3946 -1.4 (-4.4;1.7) 0.371 3867 -0.2 (-1.2;0.9) 0.734 
 
NA 
  
3821 1.8 (-0.1;3.8) 0.063 3828 0.2 (-1.0;1.5) 0.745 
3 3946 -1.1 (-4.2;2.0) 0.482 3867 0.0 (-1.0;1.1) 0.965 
 
NA 
  
3821 1.7 (-0.2;3.8) 0.087 3828 0.4 (-0.9;1.7) 0.547 
4 3946 -1.0 (-4.0;2.1) 0.530 3867 0.1 (-0.9;1.2) 0.794 
 
NA 
  
3821 1.8 (-0.2;3.8) 0.072 3828 0.5 (-0.8;1.8) 0.433 
IL-1Ra (% diff.) 1 2632 0.7 (-1.7;3.2) 0.563 2587 -1.3 (-2.1;-0.5) 0.001 242 0.0 (-1.0;0.9) 0.949 
 
2632 1.0 (-0.4;2.4) 0.155 
 
2563 -1.0 (-1.9;0.0) 0.054 
2 2632 -0.2 (-2.7;2.3) 0.867 2587 -1.5 (-2.3;-0.7) <0.001 242 -0.1 (-1.1;0.9) 0.848 
 
2632 -0.1 (-1.6;1.4) 0.859 
 
2563 -1.3 (-2.3;-0.3) 0.009 
3 2632 0.0 (-2.5;2.5) 0.992 2587 -1.5 (-2.3;-0.7) <0.001 242 -0.2 (-1.2;0.8) 0.694 
 
2632 -0.2 (-1.8;1.3) 0.773 
 
2563 -1.3 (-2.4;-0.3) 0.012 
4 2632 0.3 (-2.0;2.8) 0.780 2587 -1.2 (-2.0;-0.4) 0.004 242 -0.1 (-1.0;0.9) 0.898 
 
2632 0.2 (-1.3;1.7) 0.791 
 
2563 -0.9 (-1.9;0.1) 0.073 
Adiponectin (% diff.) 1 2631 -0.9 (-2.7;0.9) 0.311 2586 -0.1 (-0.7;0.5) 0.635 242 -0.2 (-0.9;0.5) 0.519 
 
2631 -1.3 (-2.3;-0.3) 0.009 
 
2562 -0.5 (-1.2;0.3) 0.207 
2 2631 -0.9 (-2.7;0.9) 0.314 2586 -0.1 (-0.7;0.5) 0.650 242 -0.3 (-1.0;0.4) 0.438 
 
2631 -1.6 (-2.6;-0.5) 0.005 
 
2562 -0.5 (-1.2;0.3) 0.223 
3 2631 -1.0 (-2.8;0.8) 0.274 2586 -0.1 (-0.8;0.5) 0.644 242 -0.3 (-1.0;0.5) 0.482 
 
2631 -1.6 (-2.7;-0.4) 0.007 
 
2562 -0.4 (-1.2;0.4) 0.286 
  4 2631 -1.3 (-3.0;0.4) 0.125 2586 -0.4 (-1.0;0.2) 0.177 242 -0.4 (-1.1;0.3) 0.284 
 
2631 -1.9 (-2.9;-0.8) <0.001 
 
2562 -0.8 (-1.5;0.0) 0.039 
 
n: the number of person-examinations used in the particular analysis. P: P value for the test of the effect being equal to zero. Values in bold print 
indicate significant associations after adjustment for multiple testing (128 tests) with the method of Benjamini and Hochberg. 
Page 33 of 36
eje@bioscientfica.com
Manuscript submitted for review to European Journal of Endocrinology
For Review Only
 
2 
 
Model 1: adjusted for baseline age, sex, study phase and baseline value of the outcome 
Model 2: further adjustment for baseline BMI 
Model 3: further adjustment for baseline smoking, physical activity, alcohol intake, triacylglycerols, HDL-C and LDL-C 
Model 4: further adjustment for 5-year change in BMI after baseline 
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Supplementary Table 4 Effects (with 95% CI) of a difference in insulin sensitivity or beta-cell function on 5-year changes in the inflammatory 
marker (% difference) 
 
  HOMA-IR (doubling) HOMA-β (doubling) ISI0-120 (doubling) 
Outcome Model n Estimate P n Estimate P n Estimate P 
hsCRP (% diff.) 1 3909 4.3 (1.5;7.2) 0.003 3908 4.2 (1.2;7.3) 0.006 3777 -2.0(-6.1;2.2) 0.340 
2 3909 0.7 (-2.3;3.8) 0.646 3908 1.1 (-2.0;4.3) 0.505 3777 0.8(-3.5;5.2) 0.726 
3 3909 0.9 (-2.2;4.1) 0.586 3908 1.0 (-2.2;4.4) 0.548 3777 0.2(-4.2;4.8) 0.941 
4 3909 1.1 (-1.9;4.2) 0.462 3908 1.2 (-2;4.4) 0.466 3777 -0.9(-5.1;3.5) 0.671 
IL-6 (% diff.) 1 3811 3.9 (2.2;5.6) <0.001 3810 4.3 (2.5;6.1) <0.001 3691 -2.6(-5;-0.1) 0.043 
2 3811 1.5 (-0.3;3.4) 0.105 3810 2.1 (0.2;4.1) 0.029 3691 -0.5(-3;2.1) 0.727 
3 3811 1.5 (-0.4;3.4) 0.129 3810 2.0 (0.0;4.0) 0.053 3691 -1.0(-3.7;1.7) 0.452 
4 3811 1.5 (-0.3;3.4) 0.108 3810 2.0 (0.0;4.0) 0.046 3691 -1.3(-3.9;1.3) 0.327 
IL-1Ra (% diff.) 1 2629 1.0 (-0.3;2.3) 0.139 2629 0.7 (-0.7;2.1) 0.348 2559 2.6(0.6;4.7) 0.012 
2 2629 -0.1 (-1.5;1.3) 0.880 2629 -0.3 (-1.7;1.2) 0.725 2559 3.5(1.4;5.6) <0.001 
3 2629 -0.2 (-1.6;1.3) 0.822 2629 -0.4 (-2.0;1.1) 0.569 2559 3.6(1.4;5.8) 0.001 
4 2629 0.3 (-1.2;1.7) 0.728 
 
2629 -0.1 (-1.6;1.4) 0.887 
 
2559 2.6(0.5;4.8) 0.013 
Adiponectin (% diff.) 1 2628 -1.3 (-2.2;-0.3) 0.008 2628 -1.1 (-2.1;-0.1) 0.038 2558 1.0(-0.5;2.5) 0.192 
2 2628 -1.5 (-2.5;-0.5) 0.004 2628 -1.2 (-2.2;-0.1) 0.031 2558 1.0(-0.5;2.5) 0.207 
3 2628 -1.5 (-2.6;-0.4) 0.006 2628 -1.1 (-2.2;0.0) 0.050 2558 0.9(-0.6;2.5) 0.238 
  4 2628 -1.8 (-2.8;-0.8) <0.001 2628 -1.4 (-2.4;-0.3) 0.012 2558 1.7(0.2;3.2) 0.023 
 
n: the number of person-examinations used in the particular analysis. P P value for the test of the effect being equal to zero. Values in bold print 
indicate significant associations after adjustment for multiple testing (128 tests) with the method of Benjamini and Hochberg. 
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Model 1: adjusted for baseline age, sex, study phase and baseline value of the outcome 
Model 2: further adjustment for baseline BMI 
Model 3: further adjustment for baseline smoking, physical activity, alcohol intake, triacylglycerols, HDL-C and LDL-C 
Model 4: further adjustment for 5-year change in BMI after baseline 
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